Pfizer/Astellas-Sponsored Oral Presentation

Oral Abstract Session A: Prostate Cancer

Thursday, February 16

Talazoparib

Presentation LBA17
8:00 AM – 8:10 AM

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Agarwal N

Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.

Pfizer/Alliance-Sponsored Poster Presentations

Poster Session A: Prostate Cancer

Thursday, February 16

Social determinants of health (SDOH) and survival among patients with metastatic prostate cancer (mPC): A systematic literature review (SLR)

Freedland S

Presentation 25

Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-sensitive prostate cancer

DerSarkissian M

Presentation 26
**Talazoparib**

Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer
DerSarkissian M

**Relugolix**

Real-world combination therapy patterns in patients receiving leuprolide or relugolix for androgen deprivation therapy in 2021 (The REAL-ADT COMBO Study): Analysis from a US EMR database
McKay R
Presentation is supported by Myovant and Pfizer Alliance.

**Relugolix**

Association of intermittent vs continuous androgen deprivation therapy with cardiovascular disease and endocrine/metabolic disorders in patients with metastatic prostate cancer
Morgans A
Presentation is supported by Myovant and Pfizer Alliance.

**Relugolix**

Association of intermittent or continuous androgen deprivation therapy with cardiovascular disease and endocrine/metabolic disorders in patients with nonmetastatic prostate cancer
Morgans A
Presentation is supported by Myovant and Pfizer Alliance.

**Relugolix**

Identifying prostate cancer patient subgroups based on their preferences for key attributes of androgen deprivation therapies
Collins S
Presentation is supported by Myovant and Pfizer Alliance.

**Talazoparib**

Real world (rw) racial differences in treatment (tx) patterns and clinical outcomes among patients (pts) with mCRPC
Barata P

**Talazoparib**

Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US)
Barata P
Talazoparib

Real-world homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in the United States (US)
Barata P

View Presentation

Enzalutamide

Real-world (RW) prevalence of adverse events (AEs) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)
Swami U
Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.

View Presentation

Trials in Progress Poster Session A: Prostate Cancer

Thursday, February 16 11:30 AM – 1:00 PM; 5:45 PM – 6:45 PM (PST)

Talazoparib Presentation TPS279

TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC)
Agarwal N
Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.

View Presentation

PF-06821497 Presentation TPS282

A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC)
Calvo M

View Presentation

Relugolix Presentation TPS398

A multi-center, prospective, observational study of patients with prostate cancer being treated with relugolix: OPTYX
Spratt D
Presentation is supported by Myovant and Pfizer Alliance.

View Presentation

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Friday, February 17 12:30 PM – 2:00 PM; 5:15 PM – 6:15 PM (PST)

Talazoparib Presentation 97

The impact of homologous recombination repair (HRR) gene mutation status on treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US)
Barata P

View Presentation
The prognostic value of ECOG performance status on overall survival among patients with metastatic prostate cancer: A systematic review of the literature and meta-analysis

Assayag J

Avelumab

Treatment patterns, indicators of receiving systemic treatment, and clinical outcomes in metastatic urothelial carcinoma: A retrospective analysis of real-world data in Germany

Niegisch G

Presentation is sponsored by Merck KGaA, Darmstadt, Germany, as part of a strategic global alliance with Pfizer Inc. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.

Avelumab

Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II)

Grivas P

Presentation is sponsored by Merck KGaA, Darmstadt, Germany, as part of a strategic global alliance with Pfizer Inc. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.

Avelumab

Assessment of treatment patterns and real-world outcomes following changes in the treatment paradigm for locally advanced/metastatic urothelial carcinoma (la/mUC) in the US

Kirker M

Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.

Avelumab

READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC)

Antonuzzo L

Presentation is sponsored by Merck KGaA, Darmstadt, Germany, as part of a strategic global alliance with Pfizer Inc. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.
Avelumab Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC)
Barthélémy P
Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.

Avelumab
Real-world treatment patterns and sequencing in patients with locally advanced or metastatic urothelial cancer (la/mUC) in the US
Kearney M
Presentation is sponsored by Merck KGaA, Darmstadt, Germany, as part of a strategic global alliance with Pfizer Inc. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.

Sasanlimab
Economic impact of bladder cancer (BC) in the United States (US)
Clark O

Sasanlimab
Time to event following bacillus Calmette-Guerin therapy initiation in Medicare beneficiaries with intermediate- to high-risk non-muscle invasive bladder cancer, 2010-2019
Petrilla A

Avelumab
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy
Sridhar S
Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.

Avelumab
SPADE: Design of a real-world observational study of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (UC) in the Asia-Pacific (APAC) region
SU P
Presentation is sponsored by Merck KGaA, Darmstadt, Germany, as part of a strategic global alliance with Pfizer Inc. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.

Trials in Progress Poster Session B: Urothelial Carcinoma
Friday, February 17
12:30 PM – 2:00 PM; 5:15 PM – 6:15 PM (PST)
Avelumab
SPADE: Design of a real-world observational study of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (UC) in the Asia-Pacific (APAC) region
SU P
Presentation is sponsored by Merck KGaA, Darmstadt, Germany, as part of a strategic global alliance with Pfizer Inc. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.
**Avelumab**

A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): 24-month interim results

Nathan P

Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.

**C-reactive protein (CRP) as a predictive marker for outcomes with avelumab + axitinib (A + Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101**

Tomita Y

Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.

**Axitinib**

Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

Lemelin A

**Trials in Progress**

Trials in progress: TAM kinase inhibitor PF-07265807 and sasanlimab plus axitinib in patients with advanced or metastatic renal cell carcinoma—A phase 1, open-label, pharmacokinetic, safety and tolerability study

Hirohashi T